Mariner
NRIX icon

Mariner’s Nurix Therapeutics NRIX Stock Holding History

Mariner’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$407K Sell
26,238
-1,766
-6% -$29.3K ﹤0.01% 2642
2025
Q4 		$531K Buy
+28,004
New +$402K ﹤0.01% 2404
2025
Q3 		– Sell
-26,694
Closed -$304K – 3698
2025
Q2 		$304K Sell
26,694
-4,136
-13% -$44.7K ﹤0.01% 2716
2025
Q1 		$366K Sell
30,830
-886
-3% -$14.8K ﹤0.01% 2462
2024
Q4 		$598K Sell
31,716
-79
-0.2% -$1.81K ﹤0.01% 2041
2024
Q3 		$714K Buy
31,795
+231
+0.7% +$5.23K ﹤0.01% 1867
2024
Q2 		$659K Buy
31,564
+12
+0% +$187 ﹤0.01% 1830
2024
Q1 		$464K Buy
31,552
+13
+0% +$140 ﹤0.01% 2086
2023
Q4 		$325K Sell
31,539
-388
-1% -$2.66K ﹤0.01% 2258
2023
Q3 		$251K Sell
31,927
-779
-2% -$7.11K ﹤0.01% 2312
2023
Q2 		$327K Sell
32,706
-2,509
-7% -$25.6K ﹤0.01% 2054
2023
Q1 		$313K Buy
35,215
+4,812
+16% +$50.1K ﹤0.01% 2036
2022
Q4 		$334K Buy
30,403
+397
+1% +$4.79K ﹤0.01% 1941
2022
Q3 		$391K Buy
30,006
+109
+0.4% +$1.73K ﹤0.01% 1578
2022
Q2 		$379K Buy
29,897
+773
+3% +$8.76K ﹤0.01% 1221
2022
Q1 		$408K Buy
29,124
+106
+0.4% +$1.88K ﹤0.01% 1202
2021
Q4 		$840K Buy
29,018
+18
+0.1% +$546 ﹤0.01% 874
2021
Q3 		$869K Buy
+29,000
New +$895K ﹤0.01% 732

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Mariner's NRIX Position: Q1 2026 in Review

Mariner reduced its Nurix Therapeutics (NRIX) stake by 6.3% in Q1 2026, selling an estimated $29.3K and leaving 26,238 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #2642.

Mariner first reported a position in NRIX in Q3 2021 and has held it in 18 quarters since. The position peaked at $869K in Q3 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Mariner held 26,238 shares of Nurix Therapeutics worth $407K as of Q1 2026.
  • Mariner sold 1,766 Nurix Therapeutics shares in Q1 2026, an estimated $29.3K.
  • Nurix Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2642 holding.
  • Mariner first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Mariner's Nurix Therapeutics position peaked at $869K in Q3 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.